Circulating bilirubin and defense against kidney disease and cardiovascular mortality: Mechanisms contributing to protection in clinical investigations

American Journal of Physiology - Renal Physiology

Volumn 307, Issue 2, 2014, Pages

  Boon, Ai Ching ^a   Bulmer, Andrew C ^a   Coombes, Jeff S ^b   Fassett, Robert G ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

All cause mortality; Antioxidant; Bile pigment; Hemodialysis; NADPH oxidase; Tetrapyrrole

Indexed keywords

ALBUMIN; BILIRUBIN; C REACTIVE PROTEIN; CREATININE;

ANTIHYPERTENSIVE ACTIVITY; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BILIRUBIN BLOOD LEVEL; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR MORTALITY; CELL PROLIFERATION; CELLULAR IMMUNITY; CORONARY ARTERY CALCIFICATION; CORONARY FLOW RESERVE; ENDOTHELIAL DYSFUNCTION; FOLLOW UP; HEART PROTECTION; HEART VENTRICLE PRESSURE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY INJURY; LEUKOCYTE ACTIVATION; LIVER DYSFUNCTION; LONGITUDINAL STUDY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NONHUMAN; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL PROTECTION; RETICULOENDOTHELIAL SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; SYSTEMATIC REVIEW (TOPIC); UREMIA;

ALL-CAUSE MORTALITY; ANTIOXIDANT; BILE PIGMENT; HEMODIALYSIS; NADPH OXIDASE; TETRAPYRROLE;

ANIMALS; BILIRUBIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; KIDNEY; KIDNEY DISEASES; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84904343067     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00039.2014     Document Type: Review

References (199)

1. Adin CA, Croker BP, Agarwal A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 288: F778-F784, 2005.
2. Ahmed P, Pratt A, Land VJ, Flye MW, Chaplin H. Multiple plasma exchanges successfully maintain a young adult patient with Crigler-Najjar syndrome type I. J Clin Apher 5: 17-20, 1989.
3. Ajja R, Lee DC, Sui X, Church TS, Steven NB. Usefulness of serum bilirubin and cardiorespiratory fitness as predictors of mortality in men. Am J Cardiol 108: 1438-1442, 2011.
4. Annuk M, Lind L, Linde T, Fellström B. Impaired endothelium-dependent vasodilatation in renal failure in humans. Nephrol Dial Transplant 16: 302-306, 2001.
5. Arriaga SM, Basiglio CL, Mottino AD, Almara AM. Unconjugated bilirubin inhibits C1 esterase activity. Clin Biochem 42: 919-921, 2009.
6. Basiglio CL, Arriaga SM, Pelusa F, Almara AM, Kapitulnik J, Mottino AD. Complement activation and disease: protective effects of hyperbilirubinaemia. Clin Sci 118: 99-113, 2010.
7. Betjes MG, Bajema I. The pathology of jaundice-related renal insufficiency: cholemic nephrosis revisited. J Nephrol 19: 229-233, 2006.
8. Bhan I, Thadhani R. Vascular calcification and ESRD: a hard target. Clin J Am Soc Nephrol 4: S102-S105, 2009.
9. Bhuiyan AR, Srinivasan SR, Chen W, Sultana A, Berenson GS. Association of serum bilirubin with pulsatile arterial function in asymptomatic young adults: the Bogalusa Heart Study. Metabolism 57: 612-616, 2008.
10. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938-942, 2001.
11. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 56: 1078-1083, 1999.
12. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23: 168-175, 2003.
13. Boon AC, Hawkins CL, Bisht K, Coombes JS, Bakrania B, Wagner KH, Bulmer AC. Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. Free Radic Biol Med 52: 2120-2127, 2012.
14. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 6: 652-658, 2006.
15. Bouchi R, Babazono T, Mugishima M, Yoshida N, Nyumura I, Toya K, Hanai K, Tanaka N, Ishii A, Uchigata Y, Iwamoto Y. Arterial stiffness is associated with incident albuminuria and decreased glomerular filtration rate in type 2 diabetic patients. Diabetes Care 34: 2570-2575, 2011.
16. Brown SA. Oxidative stress and chronic kidney disease. Vet Clin N Am-Small 38: 157-166, vi, 2008.
17. Bulmer AC, Blanchfield JT, Toth I, Fassett RG, Coornbes JS. Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 199: 390-396, 2008.
18. Bulmer AC, Coombes JS, Blanchfield JT, Toth I, Fassett RG, Taylor SM. Bile pigment pharmacokinetics and absorption in the rat: therapeutic potential for enteral administration. Brit J Pharmacol 164: 1857-1870, 2011.
19. Bulmer AC, Verkade HJ, Wagner KH. Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection. Prog Lipid Res 52: 193-205, 2012.
20. Carr AC, Winterbourn CC. Oxidation of neutrophil glutathione and protein thiols by myeloperoxidase-derived hypochlorous acid. Biochem J 327: 275-281, 1997.
21. Ceran C, Sonmez K, Turkyllmaz Z, Demirogullarl B, Dursun A, Duzgun E, Basaklar AC, Kale N. Effect of bilirubin in ischemia/ reperfusion injury on rat small intestine. J Pediatr Surg 36: 1764-1767, 2001.
22. Chan KH, O'Connell RL, Sullivan DR, Hoffmann LS, Rajamani K, Whiting M, Donoghoe MW, Vanhala M, Hamer A, Yu B, Stocker R, Ng MK, Keech AC. Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 56: 724-736, 2013.
23. Chen YH, Hung SC, Tarng DC. Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol 6: 567-574, 2011.
24. Chin HJ, Cho HJ, Lee TW, Na KY, Oh KH, Joo KW, Yoon HJ, Kim YS, Ahn C, Han JS, Kim S, Jeon ES, Jin DC, Kim YL, Park SH, Kim CD, Song YR, Kim SG, Kim YG, Lee JE, Oh YK, Lim CS, Lee SK, Chae DW, Cho WY, Kim HK, Jo SK. The mildly elevated serum bilirubin level is negatively associated with the incidence of end stage renal disease in patients with IgA nephropathy. J Korean Med Sci 24 Suppl: S22-S29, 2009.
25. Chin HJ, Song YR, Kim HS, Park M, Yoon HJ, Na KY, Kim Y, Chae DW, Kim S. The bilirubin level is negatively correlated with the incidence of hypertension in normotensive Korean population. J Korean Med Sci 24 Suppl: S50-S56, 2009.
26. Choi HK, Song YG, Han SH, Ku NS, Jeong SJ, Baek JH, Kim H, Kim SB, Kim CO, Kim JM, Choi JY. Clinical features and outcomes of acute kidney injury among patients with acute hepatitis A. J Clin Virol 52: 192-197, 2011.
27. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ, Motterlini R. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol Heart Circ Physiol 278: H643-H651, 2000.
28. Coombes JS, Fassett RG. Antioxidant therapy in hemodialysis patients: a systematic review. Kidney Int 81: 233-246, 2012.
29. Covic A, Kanbay M, Voroneanu L, Turgut F, Serban DN, Serban IL, Goldsmith DJ. Vascular calcification in chronic kidney disease. Clin Sci (Lond) 119: 111-121, 2010.
30. Cure E, Yuce S, Cicek Y, Cure MC. The effect of Gilbert's syndrome on the dispersions of QT interval and P-wave: an observational study. Anadolu Kardiyol Derg 13: 559-565, 2013.
31. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27-III32, 2004.
32. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction. Circulation 115: 1285-1295, 2007.
33. Deetman PE, Zelle DM, Homan van der Heide JJ, Navis GJ, Gans RO, Bakker SJ. Plasma bilirubin and late graft failure in renal transplant recipients. Transpl Int 25: 876-881, 2012.
34. Deneke SM. Thiol-based antioxidants. Curr Top Cell Regul 36: 151-180, 2000.
35. Dennery PA, Mcdonagh AF, Spitz DR, Rodgers PA, Stevenson DK. Hyperbilirubinemia results in reduced oxidative injury in neonatal gunnrats exposed to hyperoxia. Free Radic Bio Med 19: 395-404, 1995.
36. Devarajan P. The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis 17: 469-479, 2010.
37. Dobashi K, Ghosh B, Orak JK, Singh I, Singh AK. Kidney ischemiareperfusion: modulation of antioxidant defenses. Mol Cell Biochem 205: 1-11, 2000.
38. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48: 752-760, 2006.
39. Erdogan D, Gullu H, Yildirim E, Tok D, Kirbas I, Ciftci O, Baycan ST, Muderrisoglu H. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 184: 431-437, 2006.
40. Erdogan T, Cicek Y, Kocaman SA, Canga A, Cetin M, Durakoglugil E, Satiroglu O, Temiz A, Ergul E, Sahin I, Bostan M. Increased serum bilirubin level is related to good collateral development in patients with chronic total coronary occlusion. Intern Med 51: 249-255, 2012.
41. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, Salinas F, Dona S, Fagiuoli S, Sticca A, Zanus G, Cillo U, Frasson I, Destro C, Gatta A. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 45: 223-229, 2007.
42. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int 80: 806-821, 2011.
43. Fertrin KY, Goncalves MS, Saad ST, Costa FF. Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am J Med Genet 108: 117-119, 2002.
44. Fevery J. Bilirubin in clinical practice: a review. Liver Int 28: 592-605, 2008.
45. Fiaccadori E, Maggiore U, Rotelli C, Giacosa R, Lombardi M, Sagripanti S, Buratti S, Ardissino D, Cabassi A. Plasma and urinary free 3-nitrotyrosine following cardiac angiography procedures with nonionic radiocontrast media. Nephrol Dial Transplant 19: 865-869, 2004.
46. Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant 19, Suppl 5: V59-V66, 2004.
47. Folsom AR, Kronmal RA, Detrano RC, O'Leary DH, Bild DE, Bluemke DA, Budoff MJ, Liu K, Shea S, Szklo M, Tracy RP, Watson KE, Burke GL. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 168: 1333-1339, 2008.
48. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57: 1446-1454, 2008.
49. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 85: 9748-9752, 1988.
50. Fujii M, Inoguchi T, Sasaki S, Maeda Y, Zheng J, Kobayashi K, Takayanagi R. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 78: 905-919, 2010.
51. Fukui M, Tanaka M, Shiraishi E, Harusato I, Hosoda H, Asano M, Hasegawa G, Nakamura N. Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. Kidney Int 74: 1197-1201, 2008.
52. Fukui M, Tanaka M, Yamazaki M, Hasegawa G, Nishimura M, Iwamoto N, Ono T, Imai S, Nakamura N. Low serum bilirubin concentration in haemodialysis patients with type 2 diabetes. Diabetic Med 28: 96-99, 2011.
53. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376, 1980.
54. Galimberti RL, Dos Ramos Farias E, Hidalgo Parra I, Algranati L, Kowalczuk A, Imperiali N, Greloni GC, Galimberti G. Cutaneous necrosis by calcific uremic arteriolopathy. Int J Dermatol 44: 101-106, 2005.
55. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 15: 2959-2964, 2004.
56. Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal 8: 1597-1607, 2006.
57. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 172: 1461-1471, 2005.
58. Gosmanova EO, Le NA. Cardiovascular complications in CKD patients: role of oxidative stress. Cardiol Res Pract 2011: 156326, 2011.
59. Grover-Paez F, Zavalza-Gomez AB. Endothelial dysfunction and cardiovascular risk factors. Diabetes Res Clin Pract 84: 1-10, 2009.
60. Gullu H, Erdogan D, Tok D, Topcu S, Caliskan M, Ulus T, Muderrisoglu H. High serum bilirubin concentrations preserve coronary flow reserve and coronary microvascular functions. Arterioscler Thromb Vasc Biol 25: 2289-2294, 2005.
61. Guzek M, Jakubowski Z, Bandosz P, Wyrzykowski B, Smoczynski M, Jabloiska A, Zdrojewski T. Inverse association of serum bilirubin with metabolic syndrome and insulin resistance in Polish population. Przegl Epidemiol 66: 495-501, 2012.
62. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 1: 183-198, 2005.
63. Hagymási K, Kocsis I, Lengyel G, Sipos P, Fehér J, Blázovics A. Further evidence of altered redox status of hyperbilirubinaemic patients: role of bilirubin in Gilbert syndrome. Acta Biol Szeged 47: 131-134, 2003.
64. Hammerman C, Goldschmidt D, Caplan MS, Kaplan M, Bromiker R, Eidelman AI, Gartner LM, Hochman A. Protective effect of bilirubin in ischemia-reperfusion injury in the rat intestine. J Pediatr Gastroenterol Nutr 35: 344-349, 2002.
65. Han SS, Na KY, Chae DW, Kim YS, Kim S, Chin HJ. High serum bilirubin is associated with the reduced risk of diabetes mellitus and diabetic nephropathy. Tohoku J Exp Med 221: 133-140, 2010.
66. Hannken T, Schroeder R, Zahner G, Stahl RA, Wolf G. Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27(Kip1): role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol 11: 1387-1397, 2000.
67. Hansen TWR. Core concepts: bilirubin metabolism. NeoRev 11: e316-e322, 2010.
68. Heinrich M, Uder M. Pathogenesis of contrast-induced nephropathy. Am J Roentgenol 185: 1079, 2005.
69. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593-600, 2003.
70. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002.
71. Horsfall LJ, Nazareth I, Pereira SP, Petersen I. Gilbert's syndrome and the risk of death: a population-based cohort study. J Gastroenterol Hepatol 28: 1643-1647, 2013.
72. Horsfall LJ, Rait G, Walters K, Swallow DM, Pereira SP, Nazareth I, Petersen I. Serum bilirubin and risk of respiratory disease and death. JAMA 305: 691-697, 2011.
73. Huang SS, Huang PH, Chiang KH, Chen JW, Lin SJ. Association of serum bilirubin levels with albuminuria in patients with essential hypertension. Clin Biochem 44: 859-863, 2011.
74. Huang SS, Huang PH, Wu TC, Chen JW, Lin SJ. Association of serum bilirubin with contrast-induced nephropathy and future cardiovascular events in patients undergoing coronary intervention. PLoS ONE 7: e42594, 2012.
75. Hwang HJ, Kim SH. Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults. Clin Chim Acta 411: 1496-1501, 2010.
76. Ihara H, Hashizume N, Shimizu N, Aoki T. Threshold concentration of unbound bilirubin to induce neurological deficits in a patient with type I Crigler-Najjar syndrome. Ann Clin Biochem 36: 347-352, 1999.
77. Inoguchi T, Sasaki S, Kobayashi K, Takayanagi R, Yamada T. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA 298: 1398-1400, 2007.
78. Iyanagi T, Emi Y, Ikushiro Si. Biochemical and molecular aspects of genetic disorders of bilirubin metabolism. Biochim Biophys Acta 1407: 173-184, 1998.
79. 2 enzyme by bilirubin: a new role as endogenous anti-inflammatory molecule. Mol Cell Biochem 276: 219-225, 2005.
80. Jangi S, Otterbein L, Robson S. The molecular basis for the immunomodulatory activities of unconjugated bilirubin. Int J Biochem Cell Biol 45: 2843-2851, 2013.
81. Jiang F, Roberts SJ, Datla S, Dusting GJ. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 48: 950-957, 2006.
82. Johnson L, Bhutani VK. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Perinatol 35: 101-113, 2011.
83. Kaplan M, Muraca M, Hammerman C, Rubaltelli FF, Vilei MT, Vreman HJ, Stevenson DK. Imbalance between production and conjugation of bilirubin: a fundamental concept in the mechanism of neonatal jaundice. Pediatrics 110: e47, 2002.
84. Kato Y, Shimazu M, Kondo M, Uchida K, Kumamoto Y, Wakabayashi G, Kitajima M, Suematsu M. Bilirubin rinse: a simple protectant against the rat liver graft injury mimicking heme oxygenase-1 preconditioning. Hepatology 38: 364-373, 2003.
85. Kirkby K, Baylis C, Agarwal A, Croker B, Archer L, Adin C. Intravenous bilirubin provides incomplete protection against renal ischemia-reperfusion injury in vivo. Am J Physiol Renal Physiol 292: F888-F894, 2007.
86. Kitamura Y, Ishida Y, Takata K, Mizutani H, Kakimura J, Inden M, Nakata J, Taniguchi T, Tsukahara T, Akaike A, Shimohama S. Hyperbilirubinemia protects against focal ischemia in rats. J Neurosci Res 71: 544-550, 2003.
87. Koyama S, Sato Y, Tanada Y, Fujiwara H, Takatsu Y. Early evolution and correlates of urine albumin excretion in patients presenting with acutely decompensated heart failure. Circ Heart Fail 6: 227-232, 2013.
88. Kronenberg F, Coon H, Gutin A, Abkevich V, Samuels ME, Ballinger DG, Hopkins PN, Hunt SC. A genome scan for loci influencing anti-atherogenic serum bilirubin levels. Eur J Hum Genet 10: 539-546, 2002.
89. Kuchta A, Pacanis A, Kortas-Stempak B, Cwiklinska A, Zietkiewicz M, Renke M, Rutkowski B. Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res 34: 12-19, 2011.
90. Kundur AR, Bulmer AC, Singh I. Unconjugated bilirubin inhibits collagen induced platelet activation. Platelets 25: 45-50, 2014.
91. Kwak JY, Takeshige K, Cheung BS, Minakami S. Bilirubin inhibits the activation of superoxide-producing NADPH oxidase in a neutrophil cell-free system. Biochim Biophys Acta 1076: 369-373, 1991.
92. LeBlanc RM, Navar LG, Botros FT. Bilirubin exerts renoprotective effects in angiotensin II-hypertension. Am J Med Sci 340: 144-146, 2010.
93. Lee HS, Song CY. Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis. Am J Nephrol 29: 62-70, 2009.
94. Lee S, Yamada T, Osako T, Stolz DB, Abe M, McCurry KR, Murase N, Kotani J, Nakao A. Recipient hyperbilirubinaemia protects cardiac graft in rat heterotopic heart transplantation. Eur J Cardiothorac Surg 45: 481-488, 2013.
95. Libetta C, Sepe V, Esposito P, Galli F, Dal Canton A. Oxidative stress and inflammation: implications in uremia and hemodialysis. Clin Biochem 44: 1189-1198, 2011.
96. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, Kronenberg F. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 114: 1476-1481, 2006.
97. Lingenhel A, Kollerits B, Schwaiger JP, Hunt SC, Gress R, Hopkins PN, Schoenborn V, Heid IM, Kronenberg F. Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease. Exp Gerontol 43: 1102-1107, 2008.
98. Markan S, Kohli HS, Sud K, Ahuja M, Ahluwalia TS, Sakhuja V, Khullar M. Oxidative stress in primary glomerular diseases: a comparative study. Mol Cell Biochem 311: 105-110, 2008.
99. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Kihara Y, Chayama K, Noma K, Nakashima A, Tomiyama H, Takase B, Yamashina A, Higashi Y. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in gilbert syndrome. Circulation 126: 598-603, 2012.
100. Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Interv 4: 104-111, 2011.
101. Mashitani T, Hayashino Y, Okamura S, Tsujii S, Ishii H. Correlations between serum bilirubin levels and diabetic nephropathy progression among Japanese type 2 diabetes patients: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 5)]. Diabetes Care 37: 252-258, 2013.
102. Mazzone GL, Rigato I, Ostrow JD, Tiribelli C. Bilirubin effect on endothelial adhesion molecules expression is mediated by the NFkappaB signaling pathway. Biosci Trends 3: 151-157, 2009.
103. Mazzone GL, Rigato I, Tiribelli C. Unconjugated bilirubin modulates nitric oxide production via iNOS regulation. Biosci Trends 4: 244-248, 2010.
104. McCarty MF. Serum bilirubin may serve as a marker for increased heme oxygenase activity and inducibility in tissues-a rationale for the versatile health protection associated with elevated plasma bilirubin. Med Hypotheses 81: 607-610, 2013.
105. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 51: 1419-1428, 2008.
106. Melo LG, Gnecchi M, Pachori AS, Kong D, Wang K, Liu X, Pratt RE, Dzau VJ. Endothelium-targeted gene and cell-based therapies for cardiovascular disease. Arterioscler Thromb Vasc Biol 24: 1761-1774, 2004.
107. Minetti M, Mallozzi C, Di Stasi AM, Pietraforte D. Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch Biochem Biophys 352: 165-174, 1998.
108. Misra DP, Das S, Pattnaik M, Singh SC, Jena RK. Relationship of hepatic and renal dysfunction with haemorrheological parameters in Plasmodium falciparum malaria. J Assoc Physicians India 59: 552-556, 2011.
109. Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, Imaizumi T. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 101: 1002-1006, 2000.
110. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95: 560-567, 2004.
111. Moraes JA, Barcellos-de-Souza P, Rodrigues G, Nascimento-Silva V, Silva SV, Assreuy J, Arruda MA, Barja-Fidalgo C. Heme modulates smooth muscle cell proliferation and migration via NADPH oxidase: a counter-regulatory role for heme oxygenase system. Atherosclerosis 224: 394-400, 2012.
112. Nakao A, Neto JS, Kanno S, Stolz DB, Kimizuka K, Liu F, Bach FH, Billiar TR, Choi AM, Otterbein LE, Murase N. Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am J Transplant 5: 282-291, 2005.
113. Nakao A, Otterbein LE, Overhaus M, Sarady JK, Tsung A, Kimizuka K, Nalesnik MA, Kaizu T, Uchiyama T, Liu F, Murase N, Bauer AJ, Bach FH. Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology 127: 595-606, 2004.
114. Nath KA, d'Uscio LV, Juncos JP, Croatt AJ, Manriquez MC, Pittock ST, Katusic ZS. An analysis of the DOCA-salt model of hypertension in HO-1-/-mice and the Gunn rat. Am J Physiol Heart Circ Physiol 293: H333-H342, 2007.
115. Neuzil J, Stocker R. Bilirubin attenuates radical-mediated damage to serum albumin. FEBS Lett 331: 281-284, 1993.
116. Nitta K. Vascular calcification in patients with chronic kidney disease. Ther Apher Dial 15: 513-521, 2011.
117. Nitta K, Akiba T, Uchida K, Otsubo S, Otsubo Y, Takei T, Ogawa T, Yumura W, Kabaya T, Nihei H. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 27: 47-52, 2004.
118. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 228: 568-571, 2003.
119. Oda E, Aoyagi R, Aizawa Y. Hypobilirubinemia might be a possible risk factor of end-stage kidney disease independently of estimated glomerular filtration rate. Kidney Blood Press Res 36: 47-54, 2012.
120. Oh SW, Lee ES, Kim S, Na KY, Chae DW, Chin HJ. Bilirubin attenuates the renal tubular injury by inhibition of oxidative stress and apoptosis. BMC Nephrol 14: 105, 2013.
121. Okada H, Fukui M, Tanaka M, Matsumoto S, Kobayashi K, Iwase H, Tomiyasu K, Nakano K, Hasegawa G, Nakamura N. Low serum bilirubin concentration is a novel risk factor for the development of albuminuria in patients with type 2 diabetes. Metabolism 63: 409-414, 2013.
122. Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, Csizmadia E, Graca-Souza AV, Liloia A, Soares MP, Otterbein LE, Usheva A, Yamashita K, Bach FH. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 112: 1030-1039, 2005.
123. Ollinger R, Wang H, Yamashita K, Wegiel B, Thomas M, Margreiter R, Bach FH. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid Redox Signal 9: 2175-2185, 2007.
124. Ollinger R, Yamashita K, Bilban M, Erat A, Kogler P, Thomas M, Csizmadia E, Usheva A, Margreiter R, Bach FH. Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle 6: 39-43, 2007.
125. Ostrow JD, Mukerjee P, Tiribelli C. Structure and binding of unconjugated bilirubin: relevance for physiological and pathophysiological function. J Lipid Res 35: 1715-1737, 1994.
126. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.
127. Pae HO, Son Y, Kim NH, Jeong HJ, Chang KC, Chung HT. Role of heme oxygenase in preserving vascular bioactive NO. Nitric Oxide 23: 251-257, 2010.
128. Park BH, Nho HJ, Cho CG. The Association between low serum bilirubin and carotid atherosclerosis in subjects with type 2 diabetes. Endocrinol Metab 27: 126-131, 2012.
129. Peyton KJ, Shebib AR, Azam MA, Liu XM, Tulis DA, Durante W. Bilirubin inhibits neointima formation and vascular smooth muscle cell proliferation and migration. Front Pharmacol 3: 48, 2012.
130. Pflueger A, Abramowitz D, Calvin AD. Role of oxidative stress in contrast-induced acute kidney injury in diabetes mellitus. Med Sci Monit 15: RA125-RA136, 2009.
131. Pflueger A, Croatt AJ, Peterson TE, Smith LA, d'Uscio LV, Katusic ZS, Nath KA. The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am J Physiol Renal Physiol 288: F552-F558, 2005.
132. Rafat C, Burbach M, Brocheriou I, Zafrani L, Callard P, Rondeau E, Hertig A. Bilirubin-associated acute tubular necrosis in a kidney transplant recipient. Am J Kidney Dis 61: 782-785, 2013.
133. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695-701, 2002.
134. Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res 99: 801-815, 2006.
135. Raines EW, Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 69: S30-S37, 1993.
136. Ribeiro L, de Assuncao e Silva F, Kurihara RS, Schor N, Mieko E, Higa S. Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents. Kidney Int 65: 589-596, 2004.
137. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105: 2259-2264, 2002.
138. Roberts MA, Hare DL, Ratnaike S, Ierino FL. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 48: 341-360, 2006.
139. Ryter SW. Bile pigments in pulmonary and vascular disease. Front Pharmacol 3: 2012.
140. Ryu S, Chang Y, Zhang Y, Woo HY, Kwon MJ, Park H, Lee KB, Son HJ, Cho J, Guallar E. Higher serum direct bilirubin levels were associated with a lower risk of incident chronic kidney disease in middle aged korean men. PLoS ONE 9: e75178, 2014.
141. Savoia C, Sada L, Zezza L, Pucci L, Lauri FM, Befani A, Alonzo A, Volpe M. Vascular inflammation and endothelial dysfunction in experimental hypertension. Int J Hypertens 2011: 281240, 2011.
142. Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 113: 1776-1782, 2004.
143. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 109: 697-711, 2011.
144. Shin HS, Jung YS, Rim H. Relationship of serum bilirubin concentration to kidney function and 24-hour urine protein in Korean adults. BMC Nephrol 12: 29, 2011.
145. Shroff RC, Shanahan CM. The vascular biology of calcification. Semin Dial 20: 103-109, 2007.
146. Soares MP, Seldon MP, Gregoire IP, Vassilevskaia T, Berberat PO, Yu J, Tsui TY, Bach FH. Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J Immunol 172: 3553-3563, 2004.
147. Song S, Wang S, Ma J, Yao L, Xing H, Zhang L, Liao L, Zhu D. Biliverdin reductase/bilirubin mediates the anti-apoptotic effect of hypoxia in pulmonary arterial smooth muscle cells through ERK1/2 pathway. Exp Cell Res 319: 1973-1987, 2013.
148. Sowers KM, Hayden MR. Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev 3: 109-121, 2010.
149. Stec DE, Hosick PA, Granger JP. Bilirubin, renal hemodynamics and blood pressure. Front Pharmacol 3: 2012.
150. Stevenson DK, Vreman HJ, Wong RJ. Bilirubin production and the risk of bilirubin neurotoxicity. Semin Perinatol 35: 121-126, 2011.
151. Stocker R, Ames BN. Potential role of conjugated bilirubin and copper in the metabolism of lipid peroxides in bile. Proc Natl Acad Sci USA 84: 8130-8134, 1987.
152. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albuminbound bilirubin. Proc Natl Acad Sci USA 84: 5918-5922, 1987.
153. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381-1478, 2004.
154. Stocker R, Peterhans E. Synergistic interaction between vitamin E and the bile pigments bilirubin and biliverdin. Biochim Biophys Acta 1002: 238-244, 1989.
155. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 235: 1043-1046, 1987.
156. Sugimoto R, Tanaka Y, Noda K, Kawamura T, Toyoda Y, Billiar TR, McCurry KR, Nakao A. Preservation solution supplemented with biliverdin prevents lung cold ischaemia/reperfusion injury. Eur J Cardiothorac Surg 42: 1035-1041, 2012.
157. Sung KC, Shin J, Lim YH, Wild SH, Byrne CD. Relation of conjugated bilirubin concentrations to the presence of coronary artery calcium. Am J Cardiol 112: 1873-1879, 2013.
158. Tanaka M, Fukui M, Tomiyasu K, Akabame S, Nakano K, Hasegawa G, Oda Y, Nakamura N. Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis 206: 287-291, 2009.
159. Tangpukdee N, Elshiekh SB, Phumratanaprapin W, Krudsood S, Wilairatana P. Factors associated with acute renal failure in falciparum malaria infected patients. Southeast Asian J Trop Med Public Health 42: 1305-1312, 2011.
160. Tapan S, Dogru T, Tasci I, Ercin CN, Ozgurtas T, Erbil MK. Soluble CD40 ligand and soluble P-selectin levels in Gilbert's syndrome: a link to protection against atherosclerosis? Clin Biochem 42: 791-795, 2009.
161. Tapan S, Karadurmus N, Dogru T, Ercin CN, Tasci I, Bilgi C, Kurt I, Erbil MK. Decreased small dense LDL levels in Gilbert's syndrome. Clin Biochem 44: 300-303, 2011.
162. Targher G, Bosworth C, Kendrick J, Smits G, Lippi G, Chonchol M. Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Clin Chem Lab Med 47: 1055-1062, 2009.
163. Tell G, Gustincich S. Redox state, oxidative stress, and molecular mechanisms of protective and toxic effects of bilirubin on cells. Curr Pharm Des 15: 2908-2914, 2009.
164. Temme EH, Zhang J, Schouten EG, Kesteloot H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 12: 887-894, 2001.
165. Terg R, Gadano A, Cartier M, Casciato P, Lucero R, Munoz A, Romero G, Levi D, Terg G, Miguez C, Abecasis R. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int 29: 415-419, 2009.
166. Tinti F, Lai S, Umbro I, Mordenti M, Barile M, Ginanni Corradini S, Rossi M, Poli L, Nofroni I, Berloco PB, Mitterhofer AP. Chronic kidney disease-epidemiology formula and model for end-stage liver disease score in the assessment of renal function in candidates for liver transplantation. Transplant Proc 42: 1229-1232, 2010.
167. Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR. Aldosterone and arterial hypertension. Nat Rev Endocrinol 6: 83-93, 2010.
168. Tomiyama H, Tanaka H, Hashimoto H, Matsumoto C, Odaira M, Yamada J, Yoshida M, Shiina K, Nagata M, Yamashina A. Arterial stiffness and declines in individuals with normal renal function/early chronic kidney disease. Atherosclerosis 212: 345-350, 2010.
169. Toya K, Babazono T, Hanai K, Uchigata Y. Association of serum bilirubin levels with development and progression of albuminuria, and decline in estimated glomerular filtration rate in patients with type 2 diabetes mellitus. J Diabetes Investig 5: 228-235, 2013.
170. Vachharajani TJ, Work J, Issekutz AC, Granger DN. Heme oxygenase modulates selectin expression in different regional vascular beds. Am J Physiol Heart Circ Physiol 278: H1613-H1617, 2000.
171. van Slambrouck CM, Salem F, Meehan SM, Chang A. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int 84: 192-197, 2013.
172. Vasovíc O, Lalíc K, Trifunovíc D, Milíc N, Jevremovíc I, Popovíc L, Paspalj D, Milícevíc-Kalasíc A, Ševo G, Despotovíc N, Erceg P, Milosevíc DP. Prediction of cardiovascular mortality in functionally disabled elderly-a possible new score. J Med Biochem 33: 181-190, 2013.
173. Vera T, Granger JP, Stec DE. Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol 297: R738-R743, 2009.
174. Vera T, Stec DE. Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 299: R1044-R1049, 2010.
175. Vitek L. The association of elevated serum bilirubin levels and coronary heart disease. J Hepatol 39: 881-882, 2003.
176. Vitek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol 3: 55, 2012. doi: 10.3389/ fphar.2012.00055. eCollection 2012.
177. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, Novotny L, Kotal P. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 160: 449-456, 2002.
178. Vitek L, Novotny L, Sperl M, Holaj R, Spacil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 21: 408-414, 2006.
179. Vitek L, Novotny L, Zak A, Stankova B, Zima T, Polito A, Cesare G, Zerbinati C, Iuliano L. Relationship between serum bilirubin and uric acid to oxidative stress markers in Italian and Czech populations. J Appl Biomed 11: 209-221, 2013.
180. Wallner M, Marculescu R, Doberer D, Wolzt M, Wagner O, Vitek L, Bulmer AC, Wagner KH. Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome. Clin Sci (Lond) 125: 257-264, 2013.
181. Wang X, Chowdhury JR, Chowdhury NR. Bilirubin metabolism: applied physiology. Curr Paediatr 16: 70-74, 2006.
182. Watchko JF. Genetics and the risk of neonatal hyperbilirubinemia: commentary on the article by Huang et al. on page 682. Pediatr Res 56: 677-678, 2004.
183. Wegiel B, Nemeth Z, Correa-Costa M, Bulmer A, Otterbein L. Heme oxygenase-1: a metabolic nike. Antioxid Redox Signal 20: 1709-1722, 2014.
184. Wegiel B, Otterbein L. Go green: the antiinflammatory effects of biliverdin reductase. Front Pharmacol 3: 2012.
185. Wojcicka G, Beltowski J. Oxidative stress in glomerulonephritis. Postepy Hig Med Dosw 55: 855-869, 2001.
186. Wu BJ, Midwinter RG, Cassano C, Beck K, Wang Y, Changsiri D, Gamble JR, Stocker R. Heme oxygenase-1 increases endothelial progenitor cells. Arterioscler Thromb Vasc Biol 29: 1537-1542, 2009.
187. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 51: 859-862, 1996.
188. Wu TW, Fung KP, Yang CC. Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci 54: P477-P481, 1994.
189. Wu X, Feng AQ, Huang Y, Chen Y. Effect of maintenance hemodialysis in serum bilirubin. China J Modern Med 15: 1413-1417, 2005.
190. Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, Koizumi S. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 103: 129-135, 1999.
191. Yamaguchi T, Terakado M, Horio F, Aoki K, Tanaka M, Nakajima H. Role of bilirubin as an antioxidant in an ischemia-reperfusion of rat liver and induction of heme oxygenase. Biochem Biophys Res Commun 223: 129-135, 1996.
192. Yamashita K, McDaid J, Öllinger R, Tsui TY, Berberat PO, Usheva A, Csizmadia E, Smith RN, Soares MP, Bach FH. Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts. FASEB J 18: 765-767, 2004.
193. Yesilova Z, Serdar M, Ercin CN, Gunay A, Kilciler G, Hasimi A, Uygun A, Kurt I, Erbil MK, Dagalp K. Decreased oxidation susceptibility of plasma low density lipoproteins in patients with Gilbert's syndrome. J Gastroen Hepatol 23: 1556-1560, 2008.
194. Yoshida M, Tomiyama H, Yamada J, Koji Y, Shiina K, Nagata M, Yamashina A. Relationships among renal function loss within the normal to mildly impaired range, arterial stiffness, inflammation, and oxidative stress. Clin J Am Soc Nephrol 2: 1118-1124, 2007.
195. Yoshino S, Hamasaki S, Ishida S, Kataoka T, Yoshikawa A, Oketani N, Saihara K, Ichiki H, Kuwahata S, Fujita S, Takumi T, Yoshimoto I, Nakazaki M, Tei C. Characterization of the effect of serum bilirubin concentrations on coronary endothelial function via measurement of high-sensitivity C-reactive protein and high-density lipoprotein cholesterol. Heart Vessels 28: 157-165, 2013.
196. Yoshino S, Hamasaki S, Ishida S, Kataoka T, Yoshikawa A, Oketani N, Saihara K, Okui H, Shinsato T, Ichiki H, Kubozono T, Kuwahata S, Fujita S, Kanda D, Nakazaki M, Miyata M, Tei C. Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients. J Atheroscler Thromb 18: 403-412, 2011.
197. Zhang ZY, Bian LQ, Kim SJ, Zhou CC, Choi YH. Inverse relation of total serum bilirubin to coronary artery calcification score detected by multidetector computed tomography in males. Clin Cardiol 35: 301-306, 2012.
198. Zheng J, Inoguchi T, Sasaki S, Maeda Y, McCarty MF, Fujii M, Ikeda N, Kobayashi K, Sonoda N, Takayanagi R. Phycocyanin and phycocyanobilin from Spirulina platensis protect against diabetic nephropathy by inhibiting oxidative stress. Am J Physiol Regul Integr Comp Physiol 304: R110-R120, 2013.
199. Zhu C, Xiong Z, Zheng Z, Chen Y, Chen X, Qian X. Association of arterial stiffness with serum bilirubin levels in established coronary artery disease. Intern Med 51: 2083-2089, 2012.